Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial(1) prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non–small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, van...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Thorac Oncol
Autori principali: Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118909/
https://ncbi.nlm.nih.gov/pubmed/23584298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31828d08ae
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi